Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Viridian Therapeutics

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Analyst Ratings for Viridian Therapeutics

In recent months, analysts have shared a range of opinions on Viridian Therapeutics (NASDAQ: VRDN), from bullish to bearish. Here is a breakdown of the latest ratings and price targets:

Total Ratings: 2 Bullish, 4 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish.
Last 30 Days: 1 Bullish, 1 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish.
Average Price Target: Analysts have set an average price target of $35.83 for Viridian Therapeutics, with a high estimate of $40.00 and a low estimate of $30.00. The current average target represents a 3.16% decrease from the previous target of $37.00.

Key Analyst Actions and Insights

Analysts from various firms have made moves regarding Viridian Therapeutics, adjusting their ratings and price targets:

– Laura Chico from Wedbush upgraded the rating to Outperform with a price target of $40.00.
– Serge Belanger at Needham maintained a Buy rating with a price target of $30.00.
– Leland Gershell from Oppenheimer upgraded the rating to Outperform with a price target of $36.00.
– Douglas Tsao at HC Wainwright & Co. maintained a Buy rating with a price target of $37.00.
– Gregory Renza from RBC Capital kept an Outperform rating with a price target of $35.00.

Additional Insights and Resources

For more detailed information on analyst ratings and forecasts for Viridian Therapeutics, you can explore platforms like TipRanks, MarketBeat, Nasdaq, and MarketWatch. Stay informed about stock performance, analyst recommendations, and price targets by utilizing these resources for up-to-date financial market insights.

AHCO Stock Analysis: Promising Performance Indicates Potential Bullish Trend Ahead

On February 28, 2024, AHCO stock showed promising performance as it traded near the bottom of its 52-week range and above its 200-day simple moving average. This indicates that the stock may have potential for a bullish trend in the near future.

The price of AHCO shares saw a significant increase of $2.37 since the market last closed, resulting in a 31.06% rise. This positive price momentum suggests that investors are showing confidence in the company’s prospects and may be anticipating further growth.

Closing at $10.00, AHCO stock ended the day on a high note. However, in after-hours trading, the stock dropped by $0.13. While this slight decrease may be a cause for concern for some investors, it is important to note that after-hours trading can be more volatile and may not always accurately reflect the stock’s overall performance.

Overall, AHCO stock’s performance on February 28, 2024, was impressive with a significant price increase during regular trading hours. Investors will be watching closely to see if the stock can maintain its positive momentum and continue to deliver strong returns in the future.

AHCO Stock Mixed Performances: Revenue Growth but Concerning Net Income – February 28, 2024

On February 28, 2024, AHCO stock experienced mixed performances as the company released its financial results for the past year and the fourth quarter. According to data from CNN Money, AHCO reported a total revenue of $3.20 billion for the past year, representing a 7.73% increase compared to the previous year. In the fourth quarter, the company generated $858.23 million in total revenue, showing a 6.74% increase from the previous quarter.

AHCO reported a net loss of $678.89 million for the past year, marking a significant decrease of 1079.42% compared to the previous year. In the fourth quarter, the net loss improved slightly to $254.50 million, showing no change from the previous quarter.

AHCO reported an EPS of -$5.06 for the past year, indicating a sharp decline of 1114.74% compared to the previous year. In the fourth quarter, the EPS improved to -$1.91, showing a 43.18% increase from the previous quarter.

Overall, AHCO stock performances on February 28, 2024, were a mix of positive revenue growth but concerning net income and EPS figures. Investors may have reacted cautiously to the company’s financial results, considering the significant losses reported for the past year. AHCO will need to focus on improving its profitability and reducing losses to regain investor confidence and drive stock performance in the future.

Tags: AHCO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Ev clean energy

TETRA Technologies Inc Reports Strong Financial Results and Strategic Milestones for 2023

Automotive Stock Market Today

Polestar Secures 950 Million in Funding for Ambitious Growth Plans

Virios Therapeutics Advancing Antiviral Therapies for Chronic Illnesses

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com